DATALEND TRENDING - FEBRUARY 21, 2014


 

$TWTR

Twitter

$JCP

JC Penney

$ARNA

Arena Pharmaceuticals, Inc.

Utilization     95.54% 96.56% 93.82%
Short Interest 6.76% 33.25% 26.08%
Days to Cover 2.00 3.89 10.64
Fees to Borrow*
Down Down Up
*Since Previous Trading Day


SECURITIES LENDING TOP 10 EARNING EQUITIES - FEBRUARY 20, 2014


US

Utilization

1     TWITTER 96.64%
2     MYRIAD GENETICS 91.16%
3     INTEROIL 98.03%
4     ARENA PHARMACEUTICALS 93.73%
5     MINDRAY MEDICAL INTL ADR CL A 89.87%
6     VANGUARD FTSE EMERGING MARKETS ETF 96.31%
7     3D SYSTEMS 92.89%
8     WEIGHT WATCHERS INTERNATIONAL 97.76%
9     JC PENNEY 96.40%
10   SANDRIDGE ENERGY 96.34%

  • Twitter ($TWTR) fees to borrow have been trending considerably higher in recent weeks. Utilization is climbing to all-time highs since the stock price drop earlier this month.
  • Myriad Genetics ($MYGN) utilization declined a touch mid-month but has been rising again in recent days. Fees to borrow are trending lower than the peak last month.
  • Interoil ($IOC) fees to borrow are down slightly since the peak in early February. Utilization has been nearly maxed out for months.


UK

Utilization

1     BLINKX 59.13%
2     GULF KEYSTONE PETROLEUM 85.08%
3     APR ENERGY 62.05%
4     TALVIVAARA MINING 86.20%
5     STOBART GROUP 64.02%
6     QUINDELL 63.89%
7     TESCO 10.78%
8     CARPETRIGHT 46.28%
9     KAZAKHMYS 63.24%
10   NANOCO GROUP 70.23%

  • Blinkx ($BLNX.LN) fees to borrow have been trending higher as the stock price continues to decline, although utilization has dropped more than 10% since the start of February.
  • Gulf Keystone ($GKP.LN) fees to borrow have been trending slightly lower over the past week. So has the utilization. The stock price has been fairly steadily dropping so far this year.
  • The APR Energy ($APR.LN) stock price has shown some improvement since the dip at the start of the month. Fees to borrow have remained relatively stable over this period, while utilization has been gradually rising.



Europe

Utilization

1     BANCA MONTE DEI PASCHI DI SIENA (IT) 83.74%
2     PEUGEOT (FR) 84.55%
3     THROMBOGENICS 91.08%
4     UNIBAIL RODAMCO REIT (NL) 8.05%
5     OUTOTEC (FI) 85.16%
6     ACERINOX (ES) 67.64%
7     FRESENIUS (DE) 13.46%
8     GEMALTO (FR) 85.62%
9     BANCO POPOLARE (IT) 71.85%
10   MELIA HOTELS INTERNATIONAL (ES) 80.55%

  • Banca Monte Dei Paschi di Siena ($BMPS.IM) utilization has decreased a touch over the past week. Fees to borrow haven’t moved much in the past few weeks.
  • Peugeot ($UG.FP) fees to borrow have been steadily climbing since late November. Utilization continues to rise since hitting a low point in October. A deal announced this week will see a Chinese car company and the French government each take stakes in the company.
  • ThromboGenics ($THR.BB) fees to borrow have been rising for months as the stock price continues its yearlong decline. Utilization has fluctuated some in recent months but is on the rise more recently.



Far East/Australia Pacific

Utilization

1     GUNGHO ONLINE (JP) 94.50%
2     CELLTRION (KR) 74.66%
3     BYD COMPANY H (HK) 79.04%
4     GREE (JP) 89.19%
5     HANERGY SOLAR (HK) 80.62%
6     HUISHAN DAIRY 74.04%
7     ANA HOLDINGS (JP) 84.85%
8     EVERGRANDE (HK) 78.57%
9     OLAM INTERNATIONAL (SG) 72.45%
10   MONADELPHOUS GROUP (AU) 75.71%

  • GungHo Online ($3765.JP) remains Asia’s top earner as fees to borrow continue their gradual rise. Utilization has remained flat at this level for months.
  • The steady rise in Celltrion ($068270.KS) fees to borrow has stagnated in the past two weeks. Utilization is down slightly over the same period.
  • BYD Company ($1211.HK) fees to borrow have been trending steadily higher since late December. Utilization has been inching upward.

 

This is just a snapshot of the rich data and functionalities provided by DataLend. Click here for more information about DataLend's key features.



THE INFORMATION CONTAINED HEREIN IS PROPRIETARY TO EQUILEND; MAY NOT BE COPIED OR DISTRIBUTED WITHOUT THE EXPRESS CONSENT OF EQUILEND; SHALL NOT CONSTITUTE INVESTMENT ADVICE BY EQUILEND, OR ANY REPRESENTATIVE THEREOF; IS NOT WARRANTED TO BE ACCURATE, COMPLETE OR TIMELY; IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY; IS NOT INTENDED FOR TRADING PURPOSES; AND SHOULD NOT BE CONSTRUED AS EQUILEND MAKING FORECASTS, PROJECTING RETURNS OR RECOMMENDING ANY PARTICULAR COURSE OF ACTION. NEITHER EQUILEND NOR ANY REPRESENTATIVE THEREOF SHALL BE AN ADVISOR OR A FIDUCIARY OF A VISITOR TO THIS WEBSITE. EQUILEND IS NOT RESPONSIBLE OR LIABLE IN ANY WAY TO THE READER OR VISITOR, OR TO ANY PERSON, FIRM OR CORPORATION FOR ANY DAMAGES OR LOSSES ARISING FROM ANY USE OF THE INFORMATION CONTAINED HEREIN. IN CONSIDERING THE INFORMATION CONTAINED HEREIN, A VISITOR TO THIS WEBSITE DOES SO SOLELY IN RELIANCE ON THE VISITOR’S OWN JUDGMENT. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE PERFORMANCE.

DATALEND ALERTS

Sign up for weekly DataLend Top 10 email alerts



DATA ARCHIVE

March 09, 2015

March 2, 2015

February 27, 2015

January 26, 2015

November 19, 2014

November 12, 2014

November 5, 2014

October 22, 2014

October 15, 2014

October 8, 2014

September 19, 2014

September 5, 2014

August 28, 2014

August 21, 2014

July 24, 2014

June 26, 2014

June 19, 2014

June 12, 2014

June 5, 2014

May 29, 2014

May 22, 2014

May 16, 2014

May 8, 2014

May 1, 2014

April 25, 2014

April 11, 2014

April 4, 2014

March 20, 2014

March 13, 2014

March 7, 2014

February 27, 2014

February 20, 2014

February 7, 2014